New England Journal of Medicine· 2018Q1

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban et al.

6,647citations
Q1SCImago
2018year

Short summary

Adding pembrolizumab to chemotherapy significantly improved overall survival (69.2% at 12 months vs. 49.4%) and progression-free survival (8.8 months vs. 4.9 months) in previously untreated metastatic nonsquamous NSCLC patients without EGFR/ALK mutations.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine